ArticlePapillomavirus research (Amsterdam, Netherlands)2015
Seroconversion Following Anal and Genital HPV Infection in Men:
Article in Papillomavirus research (Amsterdam, Netherlands), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- [The role of serological (rapid) tests for the early detection of HPV-related cancers].Dermatologie (Heidelberg, Germany) · 2026Pooled it
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis.The Lancet. Global health · 2023Pooled it
- Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.The Journal of infectious diseases · 2016Pooled it
- Assessment of Concordant Human Papillomavirus Infection With 9-Valent Vaccine Types Across Anogenital Sites in Young Men.The Journal of infectious diseases · 2026Trial
- [Vaccine prevention of HPV-associated diseases].Dermatologie (Heidelberg, Germany) · 2026Review
- Elimination of HPV-associated cancers: universal HPV vaccination and the role of anal screening - a meeting report.BMC proceedings · 2026Article
- Evaluation of Adjuvant Administration of a Prophylactic HPV Vaccine in HPV-Positive Infertile Men: A Systematic Review.Vaccines · 2026Review
- Immune Responses to Human Papillomavirus After Infection and Vaccination.Current topics in microbiology and immunology · 2026Review
- Modelling the time to cervical cancer elimination in England: strategies for achieving elimination by 2040.BMJ public health · 2026Article
- The challenging approach to the management of male partners of HPV-positive women.Human vaccines & immunotherapeutics · 2025Review
- Persistence and clearance of oral human papillomavirus among a multi-national cohort of men.Nature communications · 2025Article
- Molecular and serological prevalence of high-risk human papillomavirus among asymptomatic men in Georgia.IJID regions · 2025Article
- Shifting HPV-cancer burden: from cervical cancer to oropharyngeal cancer.Infectious agents and cancer · 2025Article
- Naturally Acquired Genotype-Specific HPV Seroreactivity and Subsequent HPV Detection Among Heterosexual Partners.Journal of medical virology · 2025Article
- Immune responses to human papillomavirus infection and vaccination.Frontiers in immunology · 2025Review
- Health impact and cost-effectiveness analysis of gender-neutral versus female-only 9-valent human papillomavirus vaccination in Taiwan.PloS one · 2025Article
- Transcriptomic Analysis of HPV-Positive Oesophageal Tissue Reveals Upregulation of Genes Linked to Cell Cycle and DNA Replication.International journal of molecular sciences · 2024Article
- Multinational epidemiological analysis of oral human papillomavirus incidence in 3,137 men.Nature microbiology · 2024Observational
- Article
- Is immunotherapy a potential game changer in managing human papillomavirus (HPV) infection and intraepithelial neoplasia?Tumour virus research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundProtection from naturally acquired human papillomavirus (HPV) antibodies may influence HPV infection across the lifespan. This study describes seroconversion rates following genital, anal, and oral HPV 6/11/16/18 infections in men and examines differences by HPV type and anatomic site.
methodsMen with HPV 6/11/16/18 infections who were seronegative for those genotypes at the time of DNA detection were selected from the HPV Infection in Men (HIM) Study. Sera specimens collected ≤36 months after detection were analyzed for HPV 6/11/16/18 antibodies using a virus-like particle-based ELISA. Time to seroconversion was separately assessed for each anatomic site, stratified by HPV type.
resultsSeroconversion to ≥1 HPV type (6/11/16/18) in this sub-cohort (N=384) varied by anatomic site, with 6.3, 18.9, and 0.0% seroconverting following anal, genital, and oral HPV infection, respectively. Regardless of anatomic site, seroconversion was highest for HPV 6 (19.3%). Overall, seroconversion was highest following anal HPV 6 infection (69.2%). HPV persistence was the only factor found to influence seroconversion.
conclusionsLow seroconversion rates following HPV infection leave men susceptible to recurrent infections that can progress to HPV-related cancers. This emphasizes the need for HPV vaccination in men to ensure immune protection against new HPV infections and subsequent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.